Takeda Forges Alliance with Stanford University
Takeda Announces Alliance with Stanford University to Drive Therapeutic Discoveries
Collaborative aims to transform novel, innovative Stanford research into next-generation treatments for disease
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502) today announced a collaboration with Stanford University to form the Stanford Alliance for Innovative Medicines (Stanford AIM), which will help transform novel Stanford research into next-generation treatments for diseases. Through this unique collaboration, Takeda and Stanford will identify projects on the path to therapeutic discoveries and accelerate the process of bringing these drugs to market to serve patients with unmet needs.
Stanford AIM will leverage the collective knowledge and experience of Stanford and Takeda scientists in order to propel health discoveries through therapeutic development. By encouraging academic and industry scientists to work more closely together, the partnership aims to expedite promising new medicines that represent real and meaningful benefits for patients.
“Takeda’s alliance with Stanford demonstrates our commitment to advancing medicines as quickly and efficiently as possible – from drug discovery to development and ultimately to patients,” said Juan Harrison, Vice President, Head of Strategic Academic Alliances, Center for External Innovation, Takeda. “We look forward to combining the intellectual capital of Takeda and Stanford scientists, motivating both to come together as peers, in order to deliver medicines that represent real and meaningful benefits for patients.”
The partners expect to begin taking proposals from Stanford lab teams in October, which will include objectives against which to measure progress and success during key phases of research. Together, Takeda and Stanford will identify the most promising novel, innovative projects. Upon project selection, Takeda will apply its best-in-class capabilities – including scientific and clinical research and operations – to develop the pathway or platform technology.
This type of collaboration advances the validation of projects born at Stanford and improves the potential for discoveries to be developed and licensed, while exposing Takeda researchers to the latest biological discoveries and innovative chemical platforms from a leading research university. The three-year term of the collaboration will support four to eight projects running concurrently at a given time.
About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in Emerging Markets, are currently fueling the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries. For more information, visit www.takeda.com/news.
Takeda’s Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include all statements other than statements of historical fact, including plans, strategies and expectations for the future, statements regarding the expected timing of filings and approvals relating to the transaction, the expected timing of the completion of the transaction, the ability to complete the transaction or to satisfy the various closing conditions, future revenues and profitability from or growth or any assumptions underlying any of the foregoing. Statements made in the future tense, and words such as “anticipate,” “expect,” “project,” “continue,” “believe,” “plan,” “estimate,” “pro forma,” “intend,” “potential,” “target,” “forecast,” “guidance,” “outlook,” “seek,” “assume,” “will,” “may,” “should,” and similar expressions are intended to qualify as forward-looking statements. Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors and security holders are cautioned not to place undue reliance on these forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to: required regulatory approvals for the transaction may not be obtained in a timely manner, if at all; the conditions to closing of the transaction may not be satisfied; competitive pressures and developments; applicable laws and regulations; the success or failure of product development programs; actions of regulatory authorities and the timing thereof; changes in exchange rates; and claims or concerns regarding the safety or efficacy of marketed products or product candidates in development.
The forward-looking statements contained in this press release speak only as of the date of this press release, and neither Stanford nor Takeda undertake any obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If one or more of these statements is updated or corrected, investors and others should not conclude that additional updates or corrections will be made.
Kelly Schlemm – USA
Business Wire source: